149 related articles for article (PubMed ID: 7827760)
1. [Evaluation of replacement therapy in emphysema caused by alpha 1-antitrypsin deficiency].
Miravitlles M; Vidal R; Torrella M; Bofill JM; Cotrina M; de Gracia J
Arch Bronconeumol; 1994 Dec; 30(10):479-84. PubMed ID: 7827760
[TBL] [Abstract][Full Text] [Related]
2. The effects of weekly augmentation therapy in patients with PiZZ α1-antitrypsin deficiency.
Schmid ST; Koepke J; Dresel M; Hattesohl A; Frenzel E; Perez J; Lomas DA; Miranda E; Greulich T; Noeske S; Wencker M; Teschler H; Vogelmeier C; Janciauskiene S; Koczulla AR
Int J Chron Obstruct Pulmon Dis; 2012; 7():687-96. PubMed ID: 23055718
[TBL] [Abstract][Full Text] [Related]
3. Emphysema in alpha1-antitrypsin deficiency: does replacement therapy affect outcome?
Abboud RT; Ford GT; Chapman KR
Treat Respir Med; 2005; 4(1):1-8. PubMed ID: 15725045
[TBL] [Abstract][Full Text] [Related]
4. [Evaluation after 2 years of substitutive treatment of PiZZ emphysema with alpha-1 antitrypsin. 9 cases].
Carles P; Constans J; Pujazon MC; Arnaud J; Lauque D; Goudemand M
Presse Med; 1990 Mar; 19(11):514-8. PubMed ID: 2138750
[TBL] [Abstract][Full Text] [Related]
5. Exploring the optimum approach to the use of CT densitometry in a randomised placebo-controlled study of augmentation therapy in alpha 1-antitrypsin deficiency.
Parr DG; Dirksen A; Piitulainen E; Deng C; Wencker M; Stockley RA
Respir Res; 2009 Aug; 10(1):75. PubMed ID: 19678952
[TBL] [Abstract][Full Text] [Related]
6. [Replacement therapy of emphysema caused by alpha 1-antitrypsin deficiency].
Vidal R; Miravitlles M; de Gracia X; Gallego B; Morell F
Med Clin (Barc); 1991 Feb; 96(5):180-2. PubMed ID: 2033989
[TBL] [Abstract][Full Text] [Related]
7. Alpha 1 antitrypsin to treat lung disease in alpha 1 antitrypsin deficiency: recent developments and clinical implications.
Chapman KR; Chorostowska-Wynimko J; Koczulla AR; Ferrarotti I; McElvaney NG
Int J Chron Obstruct Pulmon Dis; 2018; 13():419-432. PubMed ID: 29430176
[TBL] [Abstract][Full Text] [Related]
8. The efficacy and safety of inhaled human α-1 antitrypsin in people with α-1 antitrypsin deficiency-related emphysema.
Franciosi AN; McCarthy C; McElvaney NG
Expert Rev Respir Med; 2015 Apr; 9(2):143-51. PubMed ID: 25598013
[TBL] [Abstract][Full Text] [Related]
9. SPARTA clinical trial design: exploring the efficacy and safety of two dose regimens of alpha1-proteinase inhibitor augmentation therapy in alpha1-antitrypsin deficiency.
Sorrells S; Camprubi S; Griffin R; Chen J; Ayguasanosa J
Respir Med; 2015 Apr; 109(4):490-9. PubMed ID: 25727857
[TBL] [Abstract][Full Text] [Related]
10. Pathophysiology and treatment of alpha 1-antitrypsin deficiency.
MacDonald JL; Johnson CE
Am J Health Syst Pharm; 1995 Mar; 52(5):481-9;quiz 544-5. PubMed ID: 7606551
[TBL] [Abstract][Full Text] [Related]
11. Short-term supplementation therapy does not affect elastin degradation in severe alpha(1)-antitrypsin deficiency. The American-Italian AATD Study Group.
Gottlieb DJ; Luisetti M; Stone PJ; Allegra L; Cantey-Kiser JM; Grassi C; Snider GL
Am J Respir Crit Care Med; 2000 Dec; 162(6):2069-72. PubMed ID: 11112116
[TBL] [Abstract][Full Text] [Related]
12. Augmentation therapy in alpha-1 antitrypsin deficiency: advances and controversies.
Tonelli AR; Brantly ML
Ther Adv Respir Dis; 2010 Oct; 4(5):289-312. PubMed ID: 20650978
[TBL] [Abstract][Full Text] [Related]
13. Alpha-1-antitrypsin and other proteinase inhibitors.
Miravitlles M
Curr Opin Pharmacol; 2012 Jun; 12(3):309-14. PubMed ID: 22365503
[TBL] [Abstract][Full Text] [Related]
14. Long-term augmentation therapy in twenty patients with severe alpha-1-antitrypsin deficiency--three-year follow-up.
Schwaiblmair M; Vogelmeier C; Fruhmann G
Respiration; 1997; 64(1):10-5. PubMed ID: 9044469
[TBL] [Abstract][Full Text] [Related]
15. Lung disease due to alpha 1-antitrypsin deficiency.
Wiedemann HP; Stoller JK
Curr Opin Pulm Med; 1996 Mar; 2(2):155-60. PubMed ID: 9363132
[TBL] [Abstract][Full Text] [Related]
16. A review of alpha-1 antitrypsin deficiency.
Ranes J; Stoller JK
Semin Respir Crit Care Med; 2005 Apr; 26(2):154-66. PubMed ID: 16088434
[TBL] [Abstract][Full Text] [Related]
17. Intravenous augmentation treatment and lung density in severe α1 antitrypsin deficiency (RAPID): a randomised, double-blind, placebo-controlled trial.
Chapman KR; Burdon JG; Piitulainen E; Sandhaus RA; Seersholm N; Stocks JM; Stoel BC; Huang L; Yao Z; Edelman JM; McElvaney NG;
Lancet; 2015 Jul; 386(9991):360-8. PubMed ID: 26026936
[TBL] [Abstract][Full Text] [Related]
18. Alpha-1 antitrypsin Null mutations and severity of emphysema.
Fregonese L; Stolk J; Frants RR; Veldhuisen B
Respir Med; 2008 Jun; 102(6):876-84. PubMed ID: 18353624
[TBL] [Abstract][Full Text] [Related]
19. [Prospective evaluation of clinical parameters of AAT patients with i. v. prolastin therapy in a homecare setting].
Wilke A; Grohé C
Pneumologie; 2013 Oct; 67(10):545-50. PubMed ID: 23999697
[TBL] [Abstract][Full Text] [Related]
20. Replacement therapy for alpha 1-antitrypsin deficiency associated with emphysema.
Wewers MD; Casolaro MA; Sellers SE; Swayze SC; McPhaul KM; Wittes JT; Crystal RG
N Engl J Med; 1987 Apr; 316(17):1055-62. PubMed ID: 3494198
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
